Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mildred Scheel Cancer Career Center, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Leuk Lymphoma. 2023 Nov-Dec;64(11):1801-1810. doi: 10.1080/10428194.2023.2240921. Epub 2023 Aug 8.
Patients with primary gastrointestinal (GI) lymphoma are at risk of GI perforations. Therefore, we aimed to investigate the prognostic impact of non-traumatic GI perforations. 54 patients with a histologically confirmed diagnosis of primary GI lymphoma were included. Non-traumatic lymphoma perforation occurred in ten patients (19%). Perforations occurred only in patients with aggressive B-cell lymphoma. In patients with aggressive B-cell lymphoma, the median overall survival (mOS) was 52 months (95% CI 9.88-94.12) and 27 months (95% CI 0.00-135.48) in patients with and without GI perforation, respectively. The median progression-free survival (mPFS) was 30 months (95% CI 5.6-54.4) in patients with GI perforations. In patients without lymphoma perforation, mPFS was not reached. Both mOS and mPFS did not significantly differ. In conclusion, despite the need for emergency surgery and delay in lymphoma-directed treatment, lymphoma perforation did not negatively impact our study population's OS or PFS.
原发性胃肠道（GI）淋巴瘤患者有发生 GI 穿孔的风险。因此，我们旨在研究非外伤性 GI 穿孔的预后影响。本研究纳入了 54 例经组织学证实的原发性 GI 淋巴瘤患者。10 例（19%）患者发生非外伤性淋巴瘤穿孔。穿孔仅发生在侵袭性 B 细胞淋巴瘤患者中。在侵袭性 B 细胞淋巴瘤患者中，有 GI 穿孔和无 GI 穿孔患者的中位总生存期（mOS）分别为 52 个月（95%CI9.88-94.12）和 27 个月（95%CI0.00-135.48）。有 GI 穿孔患者的中位无进展生存期（mPFS）为 30 个月（95%CI5.6-54.4）。无淋巴瘤穿孔患者的 mPFS 尚未达到。mOS 和 mPFS 均无显著差异。总之，尽管需要紧急手术和延迟淋巴瘤靶向治疗，但淋巴瘤穿孔并未对我们的研究人群的 OS 或 PFS 产生负面影响。
